Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The price of Kymera Therapeutics Inc (NASDAQ: KYMR) closed at $878.28K in the last session, up 947565% from day before closing price of $46.44. In other words, the price has increased by $947565 from its previous closing price. On the day, 0.95 million shares were traded. KYMR stock price reached its highest trading level at $46.66 during the session, while it also had its lowest trading level at $44.57.
Ratios:
We take a closer look at KYMR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.49 and its Current Ratio is at 8.49. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
On June 03, 2025, B. Riley Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $60.
BofA Securities Upgraded its Neutral to Buy on June 02, 2025, while the target price for the stock was maintained at $51.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 11 ’25 when Ridloff Elena sold 4,500 shares for $50.00 per share. The transaction valued at 225,000 led to the insider holds 0 shares of the business.
ELENA RIDLOFF bought 4,500 shares of KYMR for $218,700 on Jun 11 ’25. On Jun 03 ’25, another insider, Esposito Pamela, who serves as the Director of the company, sold 5,000 shares for $49.04 each. As a result, the insider received 245,186 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYMR now has a Market Capitalization of 2987035904 and an Enterprise Value of 2610214656. For the stock, the TTM Price-to-Sale (P/S) ratio is 50.73 while its Price-to-Book (P/B) ratio in mrq is 3.80. Its current Enterprise Value per Revenue stands at 44.327 whereas that against EBITDA is -9.608.
Stock Price History:
The Beta on a monthly basis for KYMR is 2.07, which has changed by 0.4585055 over the last 52 weeks, in comparison to a change of 0.09544468 over the same period for the S&P500. Over the past 52 weeks, KYMR has reached a high of $53.27, while it has fallen to a 52-week low of $19.44. The 50-Day Moving Average of the stock is 33.26%, while the 200-Day Moving Average is calculated to be 16.23%.
Shares Statistics:
According to the various share statistics, KYMR traded on average about 878.28K shares per day over the past 3-months and 694260 shares per day over the past 10 days. A total of 65.11M shares are outstanding, with a floating share count of 53.16M. Insiders hold about 18.37% of the company’s shares, while institutions hold 95.94% stake in the company. Shares short for KYMR as of 1748563200 were 6587317 with a Short Ratio of 7.50, compared to 1745971200 on 7184305. Therefore, it implies a Short% of Shares Outstanding of 6587317 and a Short% of Float of 12.78.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The company has 15.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.93, with high estimates of -$0.59 and low estimates of -$1.12.
Analysts are recommending an EPS of between -$2.61 and -$4.25 for the fiscal current year, implying an average EPS of -$3.6. EPS for the following year is -$4.0, with 17.0 analysts recommending between -$1.91 and -$5.4.
Revenue Estimates
A total of 20 analysts have provided revenue estimates for KYMR’s current fiscal year. The highest revenue estimate was $225M, while the lowest revenue estimate was $22.1M, resulting in an average revenue estimate of $75.3M. In the same quarter a year ago, actual revenue was $47.07M
